E
Shares of Sarepta Therapeutics (SRPT) closed the day up 22.43% after announcing additional positive phase 2b data for its Duchenne Muscular Dystrophy drug. The company stated that their drug Eteplirsen allowed patients to gain an advantage of 151 meters in the 6 minute walk test — 6MWT — compared to an external control drug study. …